Funding for this research was provided by:
National Institute of General Medical Sciences (4U54GM104944-04TBD, P20GM1033408)
National Institute of Mental Health (1R44MH112210-01A1)
National Institute of Neurological Disorders and Stroke (1R01NS111283-01)
University of Idaho Vandal Ideas Project
Text and Data Mining valid from 2020-01-21
Received: 26 July 2019
Accepted: 19 December 2019
First Online: 21 January 2020
Ethics approval and consent to participate
: This study was approved by Providence Health Care (Spokane) institutional review board (IRB SPK2087), and all subjects signed a written informed consent prior to collection of MR data. All data was de-identified before data transfer to the University of Idaho for analysis.
: All subjects in this study gave written consent for publication of de-identified data. All authors have approved the manuscript submission. The content of this manuscript has not been published or submitted for publication elsewhere.
: BAM has received grant support from Minnetronix Neuro, Alcyone Lifesciences, Voyager Therapeutics and Biogen. BAM is scientific advisory board member for Alcyone Lifesciences and the Chiari and Syringomyelia Foundation and has served as a consultant to SwanBio Therapeutics, Cerebral Therapeutics, Voyager Therapeutics, Cerevasc, Minnetronix, Medtrad Biosystems, Neurosyntek, and Behavior Imaging.